The manuscripts presents very interesting data for cardio-oncology care. I have read the article with great interest and made some comments:
1). Please add the references for the sentence:
This understanding has led to recommended maximum cumulative doxorubicin (or equivalent) dose of 450mg/m2.

2). Authors should confirm if nobody of patients had coronary artery disease or arrhythmias. Authors should add date on baseline value of left ventricular ejection fraction.

3). Authors should define more details of the pattern of follow-up of DLBCL patients after completed chemotherapy. How often was echocardiography performed ? How was asymptomatic heart failure diagnosed ? Only by occasional testing ?

4). it is difficult to agree with Authors that a proposed score is simple for daily practice. Authors should explain how they built a proposed score. More details are needed.

5). Authors should present more clear definition of CVE. It is essential especially during first year of observation after chemotherapy.

6). It is hard to believe that dose and intensity of chemotherapy did not affect cardiac and oncological prognosis. Authors should extend data about cardiotoxicity during active chemotherapy, during first year after completed chemotherapy after during later observation (every two years/ five years....)